SG11201500045RA - Factor viii complex with xten and von willebrand factor protein, and uses thereof - Google Patents
Factor viii complex with xten and von willebrand factor protein, and uses thereofInfo
- Publication number
- SG11201500045RA SG11201500045RA SG11201500045RA SG11201500045RA SG11201500045RA SG 11201500045R A SG11201500045R A SG 11201500045RA SG 11201500045R A SG11201500045R A SG 11201500045RA SG 11201500045R A SG11201500045R A SG 11201500045RA SG 11201500045R A SG11201500045R A SG 11201500045RA
- Authority
- SG
- Singapore
- Prior art keywords
- xten
- von willebrand
- viii complex
- factor
- protein
- Prior art date
Links
- 229960000301 factor viii Drugs 0.000 title 1
- 108010047303 von Willebrand Factor Proteins 0.000 title 1
- 102100036537 von Willebrand factor Human genes 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261670401P | 2012-07-11 | 2012-07-11 | |
US201361759819P | 2013-02-01 | 2013-02-01 | |
US201361801504P | 2013-03-15 | 2013-03-15 | |
US201361801544P | 2013-03-15 | 2013-03-15 | |
US201361827158P | 2013-05-24 | 2013-05-24 | |
US201361840811P | 2013-06-28 | 2013-06-28 | |
PCT/US2013/049989 WO2014011819A2 (en) | 2012-07-11 | 2013-07-10 | Factor viii complex with xten and von willebrand factor protein, and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201500045RA true SG11201500045RA (en) | 2015-02-27 |
Family
ID=49916682
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201500045RA SG11201500045RA (en) | 2012-07-11 | 2013-07-10 | Factor viii complex with xten and von willebrand factor protein, and uses thereof |
SG10201701037WA SG10201701037WA (en) | 2012-07-11 | 2013-07-10 | Factor viii complex with xten and von willebrand factor protein, and uses thereof |
SG10201913893XA SG10201913893XA (en) | 2012-07-11 | 2013-07-10 | Factor viii complex with xten and von willebrand factor protein, and uses thereof |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201701037WA SG10201701037WA (en) | 2012-07-11 | 2013-07-10 | Factor viii complex with xten and von willebrand factor protein, and uses thereof |
SG10201913893XA SG10201913893XA (en) | 2012-07-11 | 2013-07-10 | Factor viii complex with xten and von willebrand factor protein, and uses thereof |
Country Status (31)
Country | Link |
---|---|
US (3) | US10138291B2 (en) |
EP (3) | EP2882450B1 (en) |
JP (5) | JP6603128B2 (en) |
KR (2) | KR102329315B1 (en) |
CN (2) | CN110054699A (en) |
AR (1) | AR091735A1 (en) |
AU (4) | AU2013290173B2 (en) |
BR (1) | BR112015000267B1 (en) |
CA (1) | CA2878679A1 (en) |
CL (1) | CL2015000060A1 (en) |
CO (1) | CO7170123A2 (en) |
CY (1) | CY1122729T1 (en) |
DK (1) | DK2882450T3 (en) |
EA (2) | EA201792485A3 (en) |
ES (1) | ES2770501T3 (en) |
HK (1) | HK1211228A1 (en) |
HR (1) | HRP20200007T1 (en) |
HU (1) | HUE047088T2 (en) |
IL (1) | IL236412B (en) |
LT (1) | LT2882450T (en) |
MX (1) | MX2015000397A (en) |
NZ (1) | NZ703366A (en) |
PH (1) | PH12015500039A1 (en) |
PL (1) | PL2882450T3 (en) |
PT (1) | PT2882450T (en) |
RS (1) | RS59876B1 (en) |
SG (3) | SG11201500045RA (en) |
SI (1) | SI2882450T1 (en) |
TW (1) | TWI667258B (en) |
UA (1) | UA116632C2 (en) |
WO (1) | WO2014011819A2 (en) |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
LT2393828T (en) * | 2009-02-03 | 2017-01-25 | Amunix Operating Inc. | Extended recombinant polypeptides and compositions comprising same |
CA2772051C (en) | 2009-08-24 | 2020-08-18 | Amunix Operating Inc. | Coagulation factor ix compositions and methods of making and using same |
HUE046396T2 (en) | 2012-01-12 | 2020-02-28 | Bioverativ Therapeutics Inc | Chimeric factor viii polypeptides and uses thereof |
ES2935489T3 (en) | 2012-02-15 | 2023-03-07 | Bioverativ Therapeutics Inc | Factor VIII compositions and methods of preparation and use thereof |
KR102008190B1 (en) | 2012-02-15 | 2019-08-07 | 바이오버라티브 테라퓨틱스 인크. | Recombinant factor viii proteins |
EP3404105A1 (en) | 2012-07-06 | 2018-11-21 | Bioverativ Therapeutics Inc. | Cell line expressing single chain factor viii polypeptides and uses thereof |
JP6603128B2 (en) * | 2012-07-11 | 2019-11-06 | バイオベラティブ セラピューティクス インコーポレイテッド | Complex of factor VIII with XTEN and von Willebrand factor protein and uses thereof |
EP4223772A3 (en) | 2013-02-15 | 2023-10-18 | Bioverativ Therapeutics Inc. | Optimized factor viii gene |
SG11201505926VA (en) | 2013-03-15 | 2015-09-29 | Biogen Ma Inc | Factor ix polypeptide formulations |
EP2796145B1 (en) | 2013-04-22 | 2017-11-01 | CSL Ltd. | A covalent complex of von willebrand factor and faktor viii linked by a disulphide bridge |
CA2913078A1 (en) * | 2013-06-28 | 2014-12-31 | Biogen Ma Inc. | Thrombin cleavable linker with xten and its uses thereof |
US10548953B2 (en) | 2013-08-14 | 2020-02-04 | Bioverativ Therapeutics Inc. | Factor VIII-XTEN fusions and uses thereof |
SG11201605242YA (en) * | 2014-01-10 | 2016-07-28 | Biogen Ma Inc | Factor viii chimeric proteins and uses thereof |
SG11201706657PA (en) * | 2015-03-06 | 2017-09-28 | Csl Behring Recombinant Facility Ag | Compounds for improving the half-life of von willebrand factor |
EP3297656B1 (en) * | 2015-05-22 | 2020-01-08 | CSL Behring Lengnau AG | Truncated von willebrand factor polypeptides for treating hemophilia |
EA201890423A1 (en) * | 2015-08-03 | 2018-07-31 | Биовератив Терапьютикс Инк. | SLIGHT PROTEINS OF THE FACTOR IX, METHODS OF THEIR RECEPTION AND APPLICATION |
JP2018529760A (en) | 2015-08-12 | 2018-10-11 | セル マシン,インコーポレイテッド | Methods and compositions associated with long half-life coagulation complexes |
IL307276A (en) * | 2015-08-28 | 2023-11-01 | Amunix Operating Inc | Chimeric polypeptide assembly and methods of making and using the same |
SG11201805497QA (en) | 2016-01-07 | 2018-07-30 | Csl Behring Recombinant Facility Ag | Mutated truncated von willebrand factor |
BR112018015659A2 (en) | 2016-02-01 | 2018-12-26 | Bioverativ Therapeutics Inc | optimized factor viii genes |
ES2938890T3 (en) | 2016-05-20 | 2023-04-17 | Octapharma Ag | Glycosylated VWF fusion proteins with improved pharmacokinetics |
WO2017222337A1 (en) * | 2016-06-24 | 2017-12-28 | 재단법인 목암생명과학연구소 | Chimera protein comprising fviii and vwf factors, and use thereof |
CN107759697B (en) | 2016-08-19 | 2023-03-24 | 安源医药科技(上海)有限公司 | Method for producing fusion protein |
CN106279437B (en) * | 2016-08-19 | 2017-10-31 | 安源医药科技(上海)有限公司 | Hyperglycosylated human coagulation factor VIII fusion proteins and preparation method thereof and purposes |
US10738338B2 (en) | 2016-10-18 | 2020-08-11 | The Research Foundation for the State University | Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate |
WO2018087271A1 (en) | 2016-11-11 | 2018-05-17 | Csl Behring Recombinant Facility Ag | Truncated von willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder |
SG11201903950UA (en) | 2016-11-11 | 2019-05-30 | CSL Behring Lengnau AG | Truncated von willebrand factor polypeptides for treating hemophilia |
MA46967A (en) | 2016-12-02 | 2019-10-09 | Bioverativ Therapeutics Inc | METHODS OF TREATMENT OF HEMOPHILIC ARTHROPATHY USING CHEMERICAL COAGULATION FACTORS |
MX2019006446A (en) | 2016-12-02 | 2019-12-11 | Bioverativ Therapeutics Inc | Methods of inducing immune tolerance to clotting factors. |
BR112019015569A2 (en) | 2017-01-31 | 2020-03-17 | Bioverativ Therapeutics Inc. | FACTOR IX FUSION PROTEINS AND METHODS FOR THEIR PRODUCTION AND USE |
GB201707139D0 (en) * | 2017-05-04 | 2017-06-21 | Imp Innovations Ltd | Polypeptides |
JP7374883B2 (en) | 2017-08-09 | 2023-11-07 | バイオベラティブ セラピューティクス インコーポレイテッド | Nucleic acid molecules and their uses |
WO2019126576A1 (en) * | 2017-12-21 | 2019-06-27 | Amunix Pharmaceuticals, Inc. | Release segments and binding compositions comprising same |
BR112020022164A2 (en) * | 2018-05-18 | 2021-02-02 | Bioverativ Therapeutics Inc. | methods of treating hemophilia a |
JP2021533753A (en) | 2018-08-09 | 2021-12-09 | バイオベラティブ セラピューティクス インコーポレイテッド | Nucleic acid molecules and their use for non-viral gene therapy |
WO2020102741A1 (en) | 2018-11-15 | 2020-05-22 | Quantum-Si Incorporated | Methods and compositions for protein sequencing |
CA3121786A1 (en) | 2018-12-06 | 2020-06-11 | Bioverativ Therapeutics Inc. | Use of lentiviral vectors expressing factor ix |
US10654911B1 (en) * | 2019-04-02 | 2020-05-19 | Beijing Neoletix Biological Technology Co., Ltd. | Vector co-expressing truncated von Willebrand factor and factor VIII |
CA3144630A1 (en) * | 2019-06-19 | 2020-12-24 | Bioverativ Therapeutics Inc. | Methods and compositions for treating hemophilia and low bone mineral density |
CN112175088B (en) * | 2019-07-02 | 2023-03-28 | 江苏晟斯生物制药有限公司 | FIX fusion proteins, conjugates and uses thereof |
CN114364796B (en) * | 2019-09-02 | 2023-07-11 | 甘李药业股份有限公司 | Chimeric proteins |
KR20220131221A (en) | 2019-11-13 | 2022-09-27 | 아뮤닉스 파마슈티컬스, 인크. | Barcoded XTEN Polypeptides and Compositions Thereof, and Methods of Making and Using the Same |
CN113597434B (en) | 2019-12-31 | 2022-07-01 | 北京质肽生物医药科技有限公司 | Fusion proteins of GLP-1 and GDF15 and conjugates thereof |
CN113728013B (en) | 2020-01-11 | 2022-06-14 | 北京质肽生物医药科技有限公司 | Conjugates of fusion proteins of GLP-1 and FGF21 |
CN116134046A (en) * | 2020-05-20 | 2023-05-16 | 宽腾矽公司 | Methods and compositions for protein sequencing |
WO2022068920A1 (en) | 2020-09-30 | 2022-04-07 | Beijing Ql Biopharmaceutical Co., Ltd. | Polypeptide conjugates and methods of uses |
CA3220564A1 (en) | 2021-06-23 | 2022-12-29 | Bioverativ Therapeutics Inc. | Formulations of factor viii chimeric proteins and uses thereof |
CN113862301A (en) * | 2021-08-25 | 2021-12-31 | 上海交通大学医学院附属瑞金医院 | VWF propeptide expression vector and preparation method and application thereof |
Family Cites Families (144)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US4215051A (en) | 1979-08-29 | 1980-07-29 | Standard Oil Company (Indiana) | Formation, purification and recovery of phthalic anhydride |
US4713339A (en) | 1983-01-19 | 1987-12-15 | Genentech, Inc. | Polycistronic expression vector construction |
US4757006A (en) | 1983-10-28 | 1988-07-12 | Genetics Institute, Inc. | Human factor VIII:C gene and recombinant methods for production |
US4965199A (en) | 1984-04-20 | 1990-10-23 | Genentech, Inc. | Preparation of functional human factor VIII in mammalian cells using methotrexate based selection |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US4965188A (en) | 1986-08-22 | 1990-10-23 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme |
US5981216A (en) | 1985-04-01 | 1999-11-09 | Alusuisse Holdings A.G. | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
US4868112A (en) | 1985-04-12 | 1989-09-19 | Genetics Institute, Inc. | Novel procoagulant proteins |
KR910006424B1 (en) | 1985-08-21 | 1991-08-24 | 인코텍스 비.브이 | Method of manufacturing knitted briefs |
JP2525022B2 (en) | 1986-01-03 | 1996-08-14 | ジェネティックス・インスチチュ−ト・インコ−ポレ−テッド | VIII: Improved production method for c-factor protein |
US5595886A (en) | 1986-01-27 | 1997-01-21 | Chiron Corporation | Protein complexes having Factor VIII:C activity and production thereof |
US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
US5543502A (en) | 1986-06-24 | 1996-08-06 | Novo Nordisk A/S | Process for producing a coagulation active complex of factor VIII fragments |
US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
CA1331157C (en) | 1987-04-06 | 1994-08-02 | Randal J. Kaufman | Method for producing factor viii:c-type proteins |
US6060447A (en) | 1987-05-19 | 2000-05-09 | Chiron Corporation | Protein complexes having Factor VIII:C activity and production thereof |
US6346513B1 (en) | 1987-06-12 | 2002-02-12 | Baxter Trading Gmbh | Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them |
IE69026B1 (en) | 1987-06-12 | 1996-08-07 | Immuno Ag | Novel proteins with factor VIII activity process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them |
DE3720246A1 (en) | 1987-06-19 | 1988-12-29 | Behringwerke Ag | FACTOR VIII: C-LIKE MOLECULE WITH COAGULATION ACTIVITY |
FR2619314B1 (en) | 1987-08-11 | 1990-06-15 | Transgene Sa | FACTOR VIII ANALOG, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME |
US4994371A (en) | 1987-08-28 | 1991-02-19 | Davie Earl W | DNA preparation of Christmas factor and use of DNA sequences |
US6780613B1 (en) | 1988-10-28 | 2004-08-24 | Genentech, Inc. | Growth hormone variants |
US5004803A (en) | 1988-11-14 | 1991-04-02 | Genetics Institute, Inc. | Production of procoagulant proteins |
SE465222C5 (en) | 1989-12-15 | 1998-02-10 | Pharmacia & Upjohn Ab | A recombinant human factor VIII derivative and process for its preparation |
US5846951A (en) | 1991-06-06 | 1998-12-08 | The School Of Pharmacy, University Of London | Pharmaceutical compositions |
MX9204374A (en) | 1991-07-25 | 1993-03-01 | Idec Pharma Corp | RECOMBINANT ANTIBODY AND METHOD FOR ITS PRODUCTION. |
US6376463B1 (en) | 1992-04-07 | 2002-04-23 | Emory University | Modified factor VIII |
US5859204A (en) | 1992-04-07 | 1999-01-12 | Emory University | Modified factor VIII |
US5364771A (en) | 1992-04-07 | 1994-11-15 | Emory University | Hybrid human/porcine factor VIII |
US6037452A (en) | 1992-04-10 | 2000-03-14 | Alpha Therapeutic Corporation | Poly(alkylene oxide)-Factor VIII or Factor IX conjugate |
US5563045A (en) | 1992-11-13 | 1996-10-08 | Genetics Institute, Inc. | Chimeric procoagulant proteins |
SE504074C2 (en) | 1993-07-05 | 1996-11-04 | Pharmacia Ab | Protein preparation for subcutaneous, intramuscular or intradermal administration |
US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
GB9422383D0 (en) | 1994-11-05 | 1995-01-04 | Wellcome Found | Antibodies |
US6818439B1 (en) | 1994-12-30 | 2004-11-16 | Chiron Corporation | Methods for administration of recombinant gene delivery vehicles for treatment of hemophilia and other disorders |
US6086875A (en) | 1995-01-17 | 2000-07-11 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of immunogens |
US6030613A (en) | 1995-01-17 | 2000-02-29 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of therapeutics |
US6485726B1 (en) | 1995-01-17 | 2002-11-26 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of therapeutics |
US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
SE9503380D0 (en) | 1995-09-29 | 1995-09-29 | Pharmacia Ab | Protein derivatives |
US6458563B1 (en) | 1996-06-26 | 2002-10-01 | Emory University | Modified factor VIII |
EP0918872B1 (en) | 1996-08-02 | 2008-02-20 | Bristol-Myers Squibb Company | A method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulins in therapy and in vivo diagnosis |
WO1998023289A1 (en) | 1996-11-27 | 1998-06-04 | The General Hospital Corporation | MODULATION OF IgG BINDING TO FcRn |
US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
CA2225189C (en) | 1997-03-06 | 2010-05-25 | Queen's University At Kingston | Canine factor viii gene, protein and methods of use |
GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
IL138608A0 (en) | 1998-04-02 | 2001-10-31 | Genentech Inc | Antibody variants and fragments thereof |
US6242195B1 (en) | 1998-04-02 | 2001-06-05 | Genentech, Inc. | Methods for determining binding of an analyte to a receptor |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
CA2341029A1 (en) | 1998-08-17 | 2000-02-24 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
EP1006183A1 (en) | 1998-12-03 | 2000-06-07 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Recombinant soluble Fc receptors |
WO2000042072A2 (en) | 1999-01-15 | 2000-07-20 | Genentech, Inc. | Polypeptide variants with altered effector function |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
US7829085B2 (en) | 1999-07-14 | 2010-11-09 | Life Sciences Research Partners Vzw | Methods of treating hemostasis disorders using antibodies binding the C1 domain of factor VIII |
CA2747325A1 (en) | 2000-04-12 | 2001-10-25 | Human Genome Sciences, Inc. | Albumin fusion proteins |
JP2003533537A (en) | 2000-05-16 | 2003-11-11 | リポクセン テクノロジーズ リミテッド | Derivatization of proteins |
GB0029407D0 (en) | 2000-12-01 | 2001-01-17 | Affitech As | Product |
EP2341060B1 (en) | 2000-12-12 | 2019-02-20 | MedImmune, LLC | Molecules with extended half-lives, compositions and uses thereof |
WO2002076489A1 (en) | 2001-03-09 | 2002-10-03 | Dyax Corp. | Serum albumin binding moieties |
ES2425738T3 (en) | 2001-12-21 | 2013-10-17 | Human Genome Sciences, Inc. | Albumin Fusion Proteins |
KR101271635B1 (en) | 2001-12-21 | 2013-06-12 | 휴먼 게놈 사이언시즈, 인코포레이티드 | Albumin fusion proteins |
US20080194481A1 (en) | 2001-12-21 | 2008-08-14 | Human Genome Sciences, Inc. | Albumin Fusion Proteins |
US20040002587A1 (en) | 2002-02-20 | 2004-01-01 | Watkins Jeffry D. | Fc region variants |
US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
AU2003209446B2 (en) | 2002-03-01 | 2008-09-25 | Immunomedics, Inc. | Bispecific antibody point mutations for enhancing rate of clearance |
WO2003077834A2 (en) | 2002-03-15 | 2003-09-25 | The Brigham And Women's Hospital, Inc. | Central airway administration for systemic delivery of therapeutics |
EP2371389A3 (en) | 2002-08-14 | 2012-04-18 | MacroGenics, Inc. | FcgammaRIIB-specific antibodies and methods of use thereof |
US7198867B2 (en) | 2002-09-17 | 2007-04-03 | Diffusion Science, Inc. | Electrochemical generation, storage and reaction of hydrogen and oxygen |
BRPI0314814C1 (en) | 2002-09-27 | 2021-07-27 | Xencor Inc | antibody comprising an fc variant |
CA2502904C (en) | 2002-10-15 | 2013-05-28 | Protein Design Labs, Inc. | Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis |
GB2395337B (en) | 2002-11-14 | 2005-12-28 | Gary Michael Wilson | Warning Unit |
EP2368578A1 (en) | 2003-01-09 | 2011-09-28 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
US7041635B2 (en) | 2003-01-28 | 2006-05-09 | In2Gen Co., Ltd. | Factor VIII polypeptide |
DK1596887T3 (en) | 2003-02-26 | 2022-06-20 | Nektar Therapeutics | Polymer-Factor VIII conjugate |
KR100851263B1 (en) | 2003-02-28 | 2008-08-08 | 가부시키가이샤 구라레 | Curable resin composition |
US8388955B2 (en) | 2003-03-03 | 2013-03-05 | Xencor, Inc. | Fc variants |
US20090010920A1 (en) | 2003-03-03 | 2009-01-08 | Xencor, Inc. | Fc Variants Having Decreased Affinity for FcyRIIb |
WO2004101740A2 (en) | 2003-05-06 | 2004-11-25 | Syntonix Pharmaceuticals, Inc. | Clotting factor-fc chimeric proteins to treat hemophilia |
US7348004B2 (en) | 2003-05-06 | 2008-03-25 | Syntonix Pharmaceuticals, Inc. | Immunoglobulin chimeric monomer-dimer hybrids |
TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
WO2005016949A2 (en) | 2003-08-12 | 2005-02-24 | Lipoxen Technologies Limited | Sialic acid derivatives |
GB0324368D0 (en) | 2003-10-17 | 2003-11-19 | Univ Cambridge Tech | Polypeptides including modified constant regions |
US7211559B2 (en) | 2003-10-31 | 2007-05-01 | University Of Maryland, Baltimore | Factor VIII compositions and methods |
WO2005047327A2 (en) | 2003-11-12 | 2005-05-26 | Biogen Idec Ma Inc. | NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO |
WO2005077981A2 (en) | 2003-12-22 | 2005-08-25 | Xencor, Inc. | Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES |
BRPI0506771A (en) | 2004-01-12 | 2007-05-22 | Applied Molecular Evolution | antibody and pharmaceutical composition |
AU2005227326B2 (en) | 2004-03-24 | 2009-12-03 | Xencor, Inc. | Immunoglobulin variants outside the Fc region |
WO2005123780A2 (en) | 2004-04-09 | 2005-12-29 | Protein Design Labs, Inc. | Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis |
WO2006085967A2 (en) | 2004-07-09 | 2006-08-17 | Xencor, Inc. | OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS |
BRPI0510674A (en) | 2004-07-15 | 2007-12-26 | Xencor Inc | optimized fc variants |
US7566701B2 (en) | 2004-09-07 | 2009-07-28 | Archemix Corp. | Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics |
WO2006047350A2 (en) | 2004-10-21 | 2006-05-04 | Xencor, Inc. | IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION |
KR20070092754A (en) * | 2004-12-27 | 2007-09-13 | 백스터 인터내셔널 인코포레이티드 | Polymer-von willebrand factor-conjugates |
JP2009504157A (en) | 2005-08-12 | 2009-02-05 | ヒューマン ジノーム サイエンシーズ, インコーポレイテッド | Albumin fusion protein |
EP1996220B2 (en) | 2006-03-06 | 2023-08-16 | Amunix Operating Inc. | Unstructured recombinant polymers and uses thereof |
US7846445B2 (en) * | 2005-09-27 | 2010-12-07 | Amunix Operating, Inc. | Methods for production of unstructured recombinant polymers and uses thereof |
EP3896090B1 (en) | 2006-06-14 | 2022-01-12 | CSL Behring GmbH | Proteolytically cleavable fusion protein comprising a blood coagulation factor |
US20080274958A1 (en) | 2006-07-21 | 2008-11-06 | Neose Technologies, Inc. | Glycosylation of peptides via o-linked glycosylation sequences |
MX2009002816A (en) | 2006-09-14 | 2009-05-28 | Human Genome Sciences Inc | Albumin fusion proteins. |
US8969532B2 (en) | 2006-10-03 | 2015-03-03 | Novo Nordisk A/S | Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography |
MX2009003470A (en) | 2006-10-04 | 2009-04-14 | Novo Nordisk As | Glycerol linked pegylated sugars and glycopeptides. |
EP1935430A1 (en) | 2006-12-22 | 2008-06-25 | CSL Behring GmbH | Modified coagulation factors with prolonged in vivo half-life |
US8754194B2 (en) * | 2006-12-22 | 2014-06-17 | Csl Behring Gmbh | Modified coagulation factors with prolonged in vivo half-life |
SI2173890T1 (en) | 2007-06-21 | 2011-06-30 | Univ Muenchen Tech | Biological active proteins having increased in vivo and/or vitro stability |
EP2185701A4 (en) | 2007-08-15 | 2011-03-02 | Amunix Operating Inc | Compositions and methods for modifying properties of biologically active polypeptides |
AU2008319183B2 (en) | 2007-11-01 | 2014-09-04 | University Of Rochester | Recombinant factor VIII having increased stability |
JP2011503101A (en) | 2007-11-09 | 2011-01-27 | バクスター・インターナショナル・インコーポレイテッド | Modified recombinant factor VIII and von Willebrand factor and methods of use thereof |
TWI515006B (en) | 2007-12-28 | 2016-01-01 | 巴克斯特國際公司 | Recombinant vwf formulations |
KR101507718B1 (en) * | 2008-06-24 | 2015-04-10 | 체에스엘 베링 게엠베하 | Factor VIII, von Willebrand factor or complexes thereof with prolonged in vivo half-life |
WO2010060081A1 (en) | 2008-11-24 | 2010-05-27 | Bayer Healthcare Llc | Method of determining pegylated blood coagulation factor activity in a silica-based activated partial thromboplastin time assay |
LT2393828T (en) | 2009-02-03 | 2017-01-25 | Amunix Operating Inc. | Extended recombinant polypeptides and compositions comprising same |
US8680050B2 (en) | 2009-02-03 | 2014-03-25 | Amunix Operating Inc. | Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same |
US8703717B2 (en) | 2009-02-03 | 2014-04-22 | Amunix Operating Inc. | Growth hormone polypeptides and methods of making and using same |
US8957021B2 (en) | 2009-02-03 | 2015-02-17 | Amunix Operating Inc. | Glucose-regulating polypeptides and methods of making and using same |
JP2012523438A (en) | 2009-04-10 | 2012-10-04 | タフツ メディカル センター インコーポレイテッド | PAR-1 activation by metalloproteinase-1 (MMP-1) |
JP5805634B2 (en) | 2009-06-08 | 2015-11-04 | アムニクス オペレーティング インコーポレイテッド | Growth hormone polypeptides and methods of making and using the same |
EP2467166A2 (en) | 2009-08-20 | 2012-06-27 | CSL Behring GmbH | Albumin fused coagulation factors for non-intravenous administration in the therapy and prophylactic treatment of bleeding disorders |
CA2772051C (en) | 2009-08-24 | 2020-08-18 | Amunix Operating Inc. | Coagulation factor ix compositions and methods of making and using same |
WO2011028344A2 (en) | 2009-08-25 | 2011-03-10 | Amunix Operating Inc. | Interleukin-1 receptor antagonist compositions and methods of making and using same |
NZ600278A (en) | 2009-11-13 | 2014-04-30 | Grifols Therapeutics Inc | Von willebrand factor (vwf)-containing preparations, and methods, kits, and uses related thereto |
HUE036233T2 (en) * | 2009-12-06 | 2018-06-28 | Bioverativ Therapeutics Inc | Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof |
US20130040888A1 (en) * | 2010-02-16 | 2013-02-14 | Novo Nordisk A/S | Factor VIII Molecules With Reduced VWF Binding |
JP2013519699A (en) | 2010-02-16 | 2013-05-30 | ノヴォ ノルディスク アー/エス | Factor VIII fusion protein |
MX369263B (en) | 2010-05-20 | 2019-11-04 | Allergan Inc | Degradable clostridial toxins. |
US9611310B2 (en) | 2010-07-09 | 2017-04-04 | Bioverativ Therapeutics Inc. | Systems for factor VIII processing and methods thereof |
AU2011274423B2 (en) | 2010-07-09 | 2016-02-11 | Bioverativ Therapeutics Inc. | Chimeric clotting factors |
US20130017997A1 (en) | 2010-08-19 | 2013-01-17 | Amunix Operating Inc. | Factor VIII Compositions and Methods of Making and Using Same |
HUE046396T2 (en) * | 2012-01-12 | 2020-02-28 | Bioverativ Therapeutics Inc | Chimeric factor viii polypeptides and uses thereof |
KR102008190B1 (en) | 2012-02-15 | 2019-08-07 | 바이오버라티브 테라퓨틱스 인크. | Recombinant factor viii proteins |
ES2935489T3 (en) | 2012-02-15 | 2023-03-07 | Bioverativ Therapeutics Inc | Factor VIII compositions and methods of preparation and use thereof |
JP6603128B2 (en) | 2012-07-11 | 2019-11-06 | バイオベラティブ セラピューティクス インコーポレイテッド | Complex of factor VIII with XTEN and von Willebrand factor protein and uses thereof |
WO2014210547A1 (en) | 2013-06-28 | 2014-12-31 | Biogen Idec Ma Inc. | Thrombin cleavable linker |
CA2913078A1 (en) | 2013-06-28 | 2014-12-31 | Biogen Ma Inc. | Thrombin cleavable linker with xten and its uses thereof |
SG11201605242YA (en) * | 2014-01-10 | 2016-07-28 | Biogen Ma Inc | Factor viii chimeric proteins and uses thereof |
BR112020022164A2 (en) * | 2018-05-18 | 2021-02-02 | Bioverativ Therapeutics Inc. | methods of treating hemophilia a |
-
2013
- 2013-07-10 JP JP2015521785A patent/JP6603128B2/en active Active
- 2013-07-10 EA EA201792485A patent/EA201792485A3/en unknown
- 2013-07-10 LT LTEP13816031.2T patent/LT2882450T/en unknown
- 2013-07-10 KR KR1020157003523A patent/KR102329315B1/en active IP Right Grant
- 2013-07-10 CN CN201811639711.8A patent/CN110054699A/en active Pending
- 2013-07-10 PT PT138160312T patent/PT2882450T/en unknown
- 2013-07-10 SG SG11201500045RA patent/SG11201500045RA/en unknown
- 2013-07-10 SG SG10201701037WA patent/SG10201701037WA/en unknown
- 2013-07-10 SI SI201331656T patent/SI2882450T1/en unknown
- 2013-07-10 AU AU2013290173A patent/AU2013290173B2/en active Active
- 2013-07-10 NZ NZ703366A patent/NZ703366A/en unknown
- 2013-07-10 EP EP13816031.2A patent/EP2882450B1/en active Active
- 2013-07-10 MX MX2015000397A patent/MX2015000397A/en unknown
- 2013-07-10 BR BR112015000267-6A patent/BR112015000267B1/en active IP Right Grant
- 2013-07-10 CN CN201380046914.5A patent/CN104661674A/en active Pending
- 2013-07-10 DK DK13816031.2T patent/DK2882450T3/en active
- 2013-07-10 ES ES13816031T patent/ES2770501T3/en active Active
- 2013-07-10 EP EP19210390.1A patent/EP3674410A1/en not_active Withdrawn
- 2013-07-10 PL PL13816031T patent/PL2882450T3/en unknown
- 2013-07-10 RS RS20200123A patent/RS59876B1/en unknown
- 2013-07-10 SG SG10201913893XA patent/SG10201913893XA/en unknown
- 2013-07-10 EP EP23179872.9A patent/EP4269431A1/en active Pending
- 2013-07-10 US US14/413,765 patent/US10138291B2/en active Active
- 2013-07-10 WO PCT/US2013/049989 patent/WO2014011819A2/en active Application Filing
- 2013-07-10 KR KR1020217037450A patent/KR102403545B1/en active IP Right Grant
- 2013-07-10 CA CA2878679A patent/CA2878679A1/en active Pending
- 2013-07-10 EA EA201590198A patent/EA029685B1/en unknown
- 2013-07-10 HU HUE13816031A patent/HUE047088T2/en unknown
- 2013-07-11 AR ARP130102467A patent/AR091735A1/en not_active Application Discontinuation
- 2013-07-11 TW TW102124926A patent/TWI667258B/en active
- 2013-10-07 UA UAA201500228A patent/UA116632C2/en unknown
-
2014
- 2014-12-23 IL IL236412A patent/IL236412B/en active IP Right Grant
-
2015
- 2015-01-07 PH PH12015500039A patent/PH12015500039A1/en unknown
- 2015-01-09 CL CL2015000060A patent/CL2015000060A1/en unknown
- 2015-01-16 CO CO15008422A patent/CO7170123A2/en unknown
- 2015-12-08 HK HK15112122.9A patent/HK1211228A1/en unknown
-
2018
- 2018-04-06 JP JP2018073823A patent/JP2018102323A/en not_active Withdrawn
- 2018-05-08 AU AU2018203206A patent/AU2018203206B2/en active Active
- 2018-10-08 US US16/154,310 patent/US11091534B2/en active Active
-
2020
- 2020-01-03 HR HRP20200007TT patent/HRP20200007T1/en unknown
- 2020-02-05 CY CY20201100105T patent/CY1122729T1/en unknown
- 2020-03-04 JP JP2020036624A patent/JP7022165B2/en active Active
- 2020-11-05 AU AU2020264355A patent/AU2020264355A1/en not_active Abandoned
-
2021
- 2021-06-25 US US17/358,142 patent/US20220056108A1/en active Pending
- 2021-10-04 JP JP2021163423A patent/JP2022000471A/en not_active Withdrawn
-
2022
- 2022-10-10 AU AU2022252703A patent/AU2022252703A1/en active Pending
-
2023
- 2023-10-02 JP JP2023171467A patent/JP2023166024A/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1211228A1 (en) | Factor viii complex with xten and von willebrand factor protein, and uses thereof xten viii | |
HRP20190454T1 (en) | Recombinant factor viii proteins | |
HK1208827A1 (en) | Interleukin-2 fusion proteins and uses thereof -2 | |
IL238192A0 (en) | Antibodies recognizing alpha-synnuclein, compositions comprising same and uses thereof | |
IL233934B (en) | Cd47 antibodies, compositions comprising the same and uses thereof | |
IL236348A0 (en) | Anti-jagged antibodies, compositions comprising the same and uses thereof | |
HK1210790A1 (en) | Modified factor polypeptides and uses thereof | |
EP2929045A4 (en) | Protein expression enhancing polypeptides | |
EP2877854A4 (en) | Fusion proteins and methods thereof | |
EP2816626A4 (en) | Light-emitting element material, and light-emitting element | |
EP3077413A4 (en) | Polypeptides, nucleic acids and uses thereof | |
EP2930189A4 (en) | Chemokine-cytokine fusion protein and application thereof | |
EP2825548A4 (en) | Modified kisspeptin peptides and uses thereof | |
EP3049153B8 (en) | Cyclic amyloid-beta-binding peptides and the use thereof | |
EP2889307A4 (en) | Alpha-conotoxin peptide, and medical composition and purpose thereof | |
SG11201404180RA (en) | Cho-gmt recombinant protein expression | |
EP2907822A4 (en) | hnRNP A2* PROTEIN, NUCLEIC ACID FOR CODING PROTEIN AND USE THEREOF | |
EP3015548A4 (en) | Novel polypeptide, and use thereof | |
EP3015549A4 (en) | Novel polypeptide, and use thereof | |
EP3029071A4 (en) | Saxatilin-fc fusion protein and use thereof | |
EP2873676A4 (en) | Small molecular peptide and use thereof | |
GB201214974D0 (en) | Avian proteins, nucleic acids and uses thereof | |
AU2012901619A0 (en) | Fusion Proteins and Use Thereof |